Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 7/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 7/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 7/20 | 0.40 |
| ▸ | TPSAB1 | Q15661 | 7/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8491074 | 0.82 | PRSS1 (0.43) | PRSS1PRSS2PRSS3TPSAB1KMT2A | |
| SCHEMBL7499006 | 0.77 | RAB9A (0.48) | PRSS1PRSS2PRSS3TPSAB1KMT2A | |
| SCHEMBL8495148 | 0.73 | PRSS1 (0.40) | PRSS1PRSS2PRSS3TPSAB1KMT2A | |
| SCHEMBL8165421 | 0.72 | KMT2A (0.43) | PRSS1PRSS2PRSS3TPSAB1KMT2A | |
| SCHEMBL7505093 | 0.70 | PRSS1 (0.41) | PRSS1PRSS2PRSS3TPSAB1KMT2A | |
| SCHEMBL27537539 | 0.70 | PRSS1 (0.41) | PRSS1PRSS2PRSS3TPSAB1KMT2A | |
| SCHEMBL8491451 | 0.69 | ELANE (0.64) | ELANE | |
| SCHEMBL892526 | 0.69 | KMT2A (0.47) | PRSS1PRSS2PRSS3TPSAB1KMT2A | |
| SCHEMBL7199926 | 0.68 | ELANE (0.71) | ELANE | |
| SCHEMBL8189650 | 0.67 | HDAC6 (0.38) | PRSS1PRSS2PRSS3TPSAB1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6656910-B2 | Serine protease inhibitors | CORTECH, INC. | 2003-12-02 | — | — | US | disclosed |
| US-6656911-B2 | Oxadiazole ring structure peptoids which are useful as inhibitors of serine proteases | CORTECH, INC. | 2003-12-02 | — | — | US | disclosed |
| US-20030203851-A1 | Substituted oxadiazole, peptoids which are useful for treating adult respiratory distress syndrome, septic shock and myocardial ischemia-reperfusion injury | CORTECH, INC. | 2003-10-30 | — | — | US | disclosed |
| US-6608175-B2 | Oxadiazole, thiadiazoles or triazole metal derivatives reacted with an amine containing aldehyde, deprotecting, coupling with an acid and oxidizing to create substituted oxadiazole, thiadiazole or triazole peptoids | CORTECH, INC. | 2003-08-19 | — | — | US | disclosed |
| US-20030060418-A1 | Serine protease inhibitors | CORTECH, INC. | 2003-03-27 | — | — | US | disclosed |
| US-20020119998-A1 | Serine protease inhibitors | CORTECH, INC. | 2002-08-29 | — | — | US | disclosed |
| US-20020119985-A1 | Serine protease inhibitors | CORTECH, INC. | 2002-08-29 | — | — | US | disclosed |
| US-6150334-A | SUBSTITUTED OXADIAZOLE, THIADIAZOLE AND TRIAZOLE STRUCTURES WHICH ARE USEFUL AS INHIBITORS OF SERINE PROTEASES, INCLUDING HUMAN NEUTROPHIL ELASTASE | CORTECH, INC. | 2000-11-21 | — | — | US | disclosed |
| US-6015791-A | Serine protease inhibitors-cycloheptane derivatives | CORTECH INC. (US) | 2000-01-18 | — | — | US | disclosed |
| US-6001811-A | TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME, SEPSIS, MULTIPLE ORGAN FAILURE | CORTECH INC. (US) | 1999-12-14 | — | — | US | disclosed |
| US-5998379-A | USEFUL AS INHIBITORS OF SERINE PROTEASES, IN PARTICULAR HUMAN NEUTROPHIL ELASTASE, TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME, SEPTIC SHOCK, AND MYOCARDIAL ISCHEMIA-REPERFUSION INJURY | CORTECH INC. (US) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119985-A1 | Serine protease inhibitors | PRSS1, SERPINB1, SERPINE1 | PRSS1 1/4885PRSS2 11/4885PRSS3 4/4885 |
| US-20030203851-A1 | Substituted oxadiazole, peptoids which are useful for treating adult respiratory distress syndrome, septic shock and myocardial ischemia-reperfusion injury | TNNI3, PEPD, STK35 | PRSS1 19/4885PRSS2 64/4885PRSS3 5/4885 |
| US-20030060418-A1 | Serine protease inhibitors | PRSS1, SERPINB1, SERPINE1 | PRSS1 1/4885PRSS2 11/4885PRSS3 4/4885 |
| US-20020119998-A1 | Serine protease inhibitors | PRSS1, SERPINB1, SERPINE1 | PRSS1 1/4885PRSS2 11/4885PRSS3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.